Kelvin W. Gee

Professor, Pharmacology
School of Medicine

Ph.D., University of California, Davis, 1981, Pharmacology & Toxicology

Phone: (949) 824-8009, 7710
Fax: (949) 824-3451
Email: kwgee@uci.edu

University of California, Irvine
Department of Pharmacology
110C Med Surge 1
Mail Code: 4625
Irvine, CA 92697

picture of Kelvin W. Gee

Research
Interests
receptors, drug discovery, ion channels, GABA, nicotine
   
URLs Pharmacology Home Page
   
Dr. Gee's Lab
   
See below for selected publications or click here for additional publication listings available via PUB MED
   
Research
Abstract
Dr. Gee is a neuropharmacologist whose principal interests are mechanisms of regulation of signaling through ligand-gated ion channels and the identification of novel signal transduction-based therapeutic strategies for the treatment of disorders amenable to modulation of signal transduction pathways.

His laboratory is currently characterizing the pharmacology of several novel allosteric modulatory sites on the GABAA receptor complex and the a7 nicotinic receptor using tissue and recombinantly derived receptors as well as studying the behavioral consequences of modulatory site activation. These sites include for example one for certain neuroactive steroids and another for compounds related to the fluoroquinolone antibiotics.

The overall mission of the lab is to identify and characterize novel modulatory sites on ligand-gated ion channels, design and synthesize ligands for these sites and evaluate their potential as novel therapeutic agents useful in the treatment of human diseases.

PATENTS:

Gee KW, Bolger MB, Brinton RE, Burke DJ and McEwen BS: Compositions and methods for alleviating stress, anxiety and seizure activity. Serial No.089,362; 1987.

Gee KW, Bolger MB, Brinton RE, Burke D and McEwen, BS: Method, compositions and compounds for modulating brain excitability. U.S. Patent Nos. 5,120,723 and 5,208,227.

Bolger, MB, Gee KW, Lan NC, Tahir H, Belelli D, Mirsadeghi S and Purdy R: Methods, compositions and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series. U.S. Patent No. 5,232,917.

Bolger MB, Gee KW, Lan NC, Belelli D, Mirsadeghi S, Purdy R and Tahir H. Methods, compositions and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series. U.S. Patent No. 5,591,733.

Gee KW and Lan NC: Novel gamma-aminobutyric acid/benzodiazepine receptor and method for determining steroid sites in the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionophore complex. Serial No. 517,194 and 759,512; 1990.

Gee KW: Use of peripheral-type benzodiazepine sites for treatment of CNS trauma or disease. U.S. Patent No. 5,550,124.

Gee, KW and Lan, NC: Methods and compositions for inducing sleep. Serial No. 08/068,378; 1993.

Lan NC, Gee KW, Bolger MB, Tahir H, Purdy R and Upasani RB: Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series. WO 96/16076.

Lipkowski A and Gee KW– Substituted Guanidines and the Use Thereof. US Patent Application 09/625,196, Filed: July 21, 2000.

Hogenkamp DJ, Johnstone T and Gee KW: Novel quinolones for the treatment of neuropsychiatric disorders. WO 03/97564, Filed June 27, 2002.

Hogenkamp DJ, Wang JJ and Gee KW: Novel prodrugs for the oral delivery of amine-containing drugs, amino acids and peptides. US Patent Application 60/493,938, Filed August 8, 2003.

Hogenkamp DJ, Johnstone T and Gee KW: Substituted enaminones, their derivatives and uses thereof. US Patent Application 60/569,465, Filed May 6, 2004.

Hogenkamp DJ, Gee KW, Johnstone TBC: Substituted enaminones as nicotinic acetylcholine receptor modulators. International application WO 06/138510 A1, published Dec. 28, 2006.

Hogenkamp DJ, Johnstone T and Gee KW: Novel quinolones for the treatment of neuropsychiatric disorders. U.S. Patent No. 7,355,047.

Hogenkamp DJ, Johnstone T and Gee KW: Substituted enaminones, their
derivatives and uses thereof. US Patent 7,820,663

Hogenkamp DJ, Johnstone T and Gee KW: Substituted enaminones, their
derivatives and uses thereof. US Patent 7,825,278
   
Publications Ng H.J., Whittemore E.R., Tran M.B., Hogenkamp D.J., Broide R.S., Johnstone T.B.C., Zheng L., Stevens K.E. and Gee K.W. A nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. USA, 104:8059-8064, 2007.

Hogenkamp D.J., Johnstone T.B.C., Huang J-C., Li W-Y., Tran M., Whittemore E.R., Bagnera R.E. and Gee K.W. Enaminone amides as novel orally active GABAA receptor modulators, J. Med. Chem., 50:3369-3379, 2007.

Yoshimura R.F., Hogenkamp D.J., Li W-Y., Tran M., Belluzi J.D., Whittemore E.R., Leslie F.M. and Gee K.W. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats, J Pharmacol Exp Ther 323:907-915, 2007.

Gee KW, Tran MB, Hogenkamp DJ, Johnstone TB, Bagnera RE, Yoshimura RF, Huang J-C, Belluzzi JD and Whittemore ER: Limiting activity at b1-subunit containing GABAA receptor subtypes reduces sedative liability, J Pharmacol Exp Ther 332:1040-1053, 2010.

Johnstone TBJ, Gu Z, Yoshimura RF, Villegier AS, Hogenkamp DJ, Whittemore ER, Huang JC, Tran MB, Belluzzi JD, Yakel JL and Gee KW: Allosteric modulation of related ligand-gated ion channels synergistically induces long term potentiation in the hippocampus and enhances cognition, J Pharmacol Exp Ther 336:908-915, 2011.

Hogenkamp DJ, Ford-Hutchinson T, Yoshimura RF, Tran MB, Johnstone TBJ, Bascom G, Rollins H, Lu L, Whittemore ER and Gee KW: Design, synthesis and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of a7 nicotinic acetylcholine receptors. J Med Chem 56:8352-8365, 2013.

Hogenkamp DJ, Tran MB, Yoshimura RF, Johnstone TB and Gee KW: Pharmacological profile of a 17ß-heteroaryl-substituted neuroactive steroid. Psychopharmacol (Berl) 231:3517-3524, 2014.

Yoshimura RF, Tran MB, Hogenkamp DJ, Johnstone TBJ and Gee KW: Limited central side effects of a ?beta-subunit subtype selective GABAA receptor allosteric modulator. J Psychopharmacol 28:472-478, 2014.
   
Grants University of Colorado, Denver, Federal Flow Through from NIMH U01 MH094247, Robert Freeman, M.D., Prime Award P.I., #FY12.083.006, 09/21/11-08/31/16, $526,640 direct costs, Human trial of allosteric modulator of alpha7 nicotinic receoptor in schizophrenia (Role: P.I. of sub-award).
   
Department of Defense (U.S. Army), Congressionally Directed Medical Research Programs, W81XWH-13-1-0144, 8/31/13 - 9/1/15, $399,799 diect cost, Dual Modulators of GABA-A and Alpha7 Nicotinic Receptors for Treating Autism (Role: PI).
   
Professional
Societies
American Society for Pharmacology and Experimental Therapeutics
The Society for Neuroscience
Western Pharmacology Society
The American Society for Neurochemistry
Sigma Xi
   
Graduate Programs Pharmacological Sciences

Interdepartmental Neuroscience Program

Medicinal Chemistry and Pharmacology

   
Research Center The Center for Autism & Neurodevelopmental Disorders
   
   
Link to this profile http://www.faculty.uci.edu/profile.cfm?faculty_id=2310
   
Last updated 12/08/2015